Life-changing eczema medication avoids $20K price hike

Greg Giles has struggled with debilitating eczema for most of his life, relying on the injectable treatment Dupixent for relief. Nearly 20,000 Australians have turned to the medication since it was included in the Pharmaceutical Benefit Scheme in 2021, with its effectiveness and minimal side effects making it a popular choice. Despite concerns of being pulled from the PBS due to costs, a new deal has been secured to ensure continued access to the treatment, providing relief for patients and reducing healthcare expenses.

Full Article